Hemorol rectal suppositories №6х2

Name:
Hemorol supp No. 12
Description:
Torpedo-shaped suppositories, brown in color, with a peculiar smell, with permissible: lighter ellipsoidal ending, white coating on the surface of the suppository and stripes from light brown to dark brown. The main active ingredient 1 suppository (2 g) contains: extract of dense chamomile Release form The drug is produced in the form of rectal suppositories packaged in packs of 12 pieces. Dosage The suppository should be removed from the foil bladder and inserted into the rectum, preferably in the supine position (it is most convenient to use the suppository at night before going to bed). Usually it is used once a day, however, in the later stages of hemorrhoids, use up to 2-3 times a day is allowed. Treatment with Hemorol suppositories should last 7 days. If there is no improvement after this time, a doctor should be consulted, preferably a specialist proctologist (i.e. a specialized surgeon dealing with diseases of the colon and rectum). Special instructions If blood is found in the stool, consult a doctor. Due to sensitization to benzocaine, it is recommended to interview the patient’s susceptibility to sensitization and not to exceed 7 days of use. In the absence of action or exacerbation of cahoral symptoms, the drug should be discontinued. In the case of large hemorrhoids, pressure soreness may occur until the suppository is dissolved (approximately 5-10 minutes). Pharmacological action Other agents for the treatment of hemorrhoids and anal fissures for topical use. ATS code: C05AX03. PharmacodynamicsHemorol is a multicomponent drug, the therapeutic effect of which is due to the pharmacological properties of the active components that make up its composition. The drug has antispasmodic, local anesthetic and anti-inflammatory effects. Indications for use Local symptomatic treatment of the initial stage of uncomplicated hemorrhoids after consulting a doctor. Dosage and administration Before use, tear the triangular end of the film, remove the suppository from the blister and insert it into the rectum. Adults are prescribed rectally 1 suppository at night, in more severe cases – 2-3 suppositories during the day. The duration of therapy is determined by the doctor individually, depending on the effect achieved and the tolerability of the drug. The duration of treatment should not exceed 7 days. Use during pregnancy and lactation Due to the risk of an abortive effect (Zarnovets herb extract, escin), the drug should not be used by pregnant women. The safety of the drug in breastfeeding women has not been studied. Precautions In the presence of large hemorrhoids after the introduction of the suppository, pain may appear due to the pressure of the suppository on the hemorrhoids, the pain may last for 5-10 minutes. until the suppository dissolves. When using the drug, kidney function should be monitored. Use with caution in patients with prostatic hypertrophy without urinary tract obstruction; with Down’s disease; with cerebral palsy; patients with mild to moderate renal insufficiency; with reflux esophagitis, with a hernia of the esophageal opening of the diaphragm, combined with reflux esophagitis; with inflammatory bowel diseases, including ulcerative colitis and Crohn’s disease, megacolon; patients with xerostomia; elderly patients, debilitated patients; in chronic lung diseases accompanied by bronchial obstruction; in chronic lung diseases, accompanied by the formation of difficult-to-separate sputum, especially in debilitated patients; with autonomic (autonomous) neuropathy; with organic diseases of the nervous system. If there is no effect or worsening of the condition (severe pain, anal bleeding, suspected blood in the stool, as well as other alarming symptoms), stop using the drug and consult a doctor. This medicinal product contains benzocaine. After the use of the drug, methemoglobinemia may develop. Symptoms of the development of methemoglobinemia: pale, gray or bluish color of the skin, lips and nail plates, headache, dizziness, shortness of breath, general weakness and tachycardia. These symptoms indicate the development of moderate or severe methemoglobinemia and a significant decrease in the oxygen capacity of the blood. The characteristic color of the blood (blood is not scarlet, but chocolate brown) may indicate the development of methemoglobinemia, but these changes appear at a late stage of the disease. Symptoms may appear within a few minutes to one or two hours after using benzocaine-containing products. Symptoms may develop after the first or repeated use of benzocaine-containing products. Patients with diseases of the respiratory system (bronchial asthma, bronchitis or emphysema, patients with heart disease, smokers) have an increased risk of developing complications associated with methemoglobinemia. Children under four months of age, elderly patients, and patients with certain birth defects (glucose-6-phosphodiesterase deficiency, hemoglobin M disease, NADH-methemoglobin reductase (diaphorase 1) deficiency, pyruvate kinase deficiency) are at increased risk of developing methemoglobinemia. With the simultaneous use of drugs, foods and water containing nitrites and nitrates, the risk of methemoglobin formation increases. Use in children The use of the drug in children under the age of 18 years is not recommended due to the lack of adequate data. Interaction with other drugs When used with MAO inhibitors, cardiac arrhythmias occur, with quinidine, novocainamide, a summation of the anticholinergic effect is observed. May reduce the duration and depth of action of narcotic drugs, weakens the analgesic effect of opiates. With simultaneous use with dimedrol or diprazine, the effect of the drug is enhanced, with nitrates, haloperidol, corticosteroids for systemic use – the likelihood of an increase in intraocular pressure increases, with sertraline – the depressive effect of both drugs increases; with spironolactone, minoxidil – the effect of spironolactone and minoxidil is reduced, with penicillins – the effect of both drugs is enhanced, with nizatidine – the effect of nizatidine is enhanced, with ketoconazole – the absorption of ketoconazole is reduced, with ascorbic acid and attapulgite – the effect of atropine is reduced, with pilocarpine – the effect of pilocarpine is reduced in the treatment of glaucoma, with oxprenolone – the antihypertensive effect of the drug is reduced. Under the action of octadine, a decrease in the hyposecretory effect of atropine is possible. Atropine weakens the action of M-cholinomimetics and anticholinesterase agents. With simultaneous use with sulfanilamide drugs, the risk of kidney damage increases, with drugs containing potassium, the formation of intestinal ulcers is possible, with non-steroidal anti-inflammatory drugs, the risk of gastric ulcers and bleeding. The effect of the drug may be enhanced with the simultaneous use of other drugs with an antimuscarinic effect: M-anticholinergics, antiparkinsonian drugs (amantadine), antispasmodics, some antihistamines, drugs of the butyrophenone group, phenothiazines, quinidine and tricyclic antidepressants, disopyramide, selective monoamine reuptake inhibitors. Inhibition of peristalsis by atropine may alter the absorption of other drugs. The drug may enhance the effect of antithrombotic agents. Cephalosporin antibiotics increase the concentration of free escin in the blood and the risk of side effects. Simultaneous use with antibacterial agents of the aminoglycoside group should be avoided due to the increased toxic effect of aminoglycosides on the kidneys. Contraindications Hypersensitivity to the components of the drug, other anesthetics from the group of amides, plants of the Asteraceae family. Oncological diseases of the colon. Granulocytopenia, increased blood clotting, thromboembolic disease. Glaucoma. Severe renal failure. Liver failure. Diseases of the cardiovascular system, in which an increase in heart rate may be undesirable; atrial fibrillation, tachycardia, chronic heart failure, and coronary heart disease, mitral stenosis, severe arterial hypertension. Prostate hypertrophy with urinary retention, predisposition to urinary retention. Myasthenia. Diseases of the digestive tract, accompanied by obstruction. hyperthermia syndrome. thyrotoxicosis. Acute bleeding. Pregnancy, lactation, children under 18 years of age. Ingredients: Thick extract of chamomile flowers – 50 mg (Matricariae flos extraction spissum) (3:1) extractant: purified waterDense belladonnae root extract – 20 mg (Belladonnae radicis extractum spissum) (4:1) extractant: ethanol 70% v / v Thick complex extract (4:1) – 80 mg from: scorching herb (Cytisi scoparii herbae) (1 hour), horse chestnut bark (Hippocastani corticis) (1 hour), cinquefoil rhizome (Tormentillae rhizomae) (1 hour), yarrow herb (Millefolii herbae) (1 hour) extractant: ethanol 40% v / v Benzocaine (Benzocainum) – 100 mg Excipients: Glycerin (E 422) – 150 mg Solid fat – up to 2 g , vomiting, agitation, irritability, tremor, convulsions, insomnia, drowsiness, hallucinations, hyperthermia, depression of the central nervous system, depression of the activity of the respiratory and vasomotor centers. Treatment: gastric lavage, parenteral administration of cholinomimetics and anticholinesterase agents. Therapy is symptomatic. The ability to influence the reaction rate when driving vehicles or working with other mechanisms Studies to evaluate the effect of the use of the drug on the ability to drive a car and work with moving mechanisms have not been conducted. In case of side effects from the nervous system or organs of vision, you should refrain from driving vehicles and working with mechanisms. Side effects When using the drug, local reactions may occur at the injection site, including itching, rash, skin flushing. From the immune system: allergic reactions, including angioedema, anaphylactic reactions, anaphylactic shock. From the skin and subcutaneous tissue: skin rash, itching, hyperemia, urticaria, skin edema, feeling of heat, exfoliative dermatitis. On the part of the digestive tract: dry mouth, thirst, impaired taste sensations, dysphagia, decreased intestinal motility until the development of atony, constipation, decreased tone of the biliary tract and gallbladder. On the part of the organs of vision: dilated pupils, photophobia, accommodation paralysis, increased intraocular pressure, temporary visual disturbances. On the part of the respiratory system: a decrease in secretory activity and bronchial tone, which leads to the formation of viscous sputum, difficulty coughing up sputum. From the nervous system: psychomotor agitation, convulsions, headache, dizziness. From the side of the cardiovascular system: palpitations, tachycardia, arrhythmia (including extrasystole); myocardial ischemia, arterial hypotension, facial flushing, hot flashes. From the urinary system: difficulty and urinary retention. Other reactions: methemoglobinemia, decreased sweating, dry skin, dysarthria. Storage conditions Store at temperatures up to 25 ° C, out of the reach and sight of children. NOTE! On the surface of the candle, the presence of white plaque is allowed. This does not affect the quality and effectiveness of the drug. Buy Hemorol rectal suppositories No. 6×2 Price for Hemorol rectal suppositories No. 6×2